生物技术公司AlphaRose Therapeutics宣布收购Alpha Anomeric-动脉网

AlphaRose Therapeutics Announces Acquisition of Alpha Anomeric SA, a French Company with Industry-Leading Oligonucleotide Technology

CISION 等信源发布 2025-04-29 20:34



可切换为仅中文







Acquisition positions AlphaRose as a leader in next generation Antisense Oligonucleotide Therapeutics with a novel proprietary oligonucleotide chemistry (abcDNA) platform invented at University of

收购使AlphaRose成为下一代反义寡核苷酸治疗领域的领导者，其拥有一个新型的专有寡核苷酸化学（abcDNA）平台，该平台发明于大学。

Bern, Switzerland

伯尔尼，瑞士

Establishes a presence for AlphaRose in

在以下地点为 AlphaRose 建立了业务 presence

Europe

欧洲

, with Alpha Anomeric headquartered in

，Alpha Anomeric 总部位于

Paris, France

法国巴黎

abcDNA Chemistry platform validated in ASO gapmer constructs, a core focus of AlphaRose Therapeutics' programs

abcDNA化学平台在ASO缺口构建体中得到验证，这是AlphaRose Therapeutics项目的核心重点

AUSTIN, Texas

德克萨斯州奥斯汀

，

April 29, 2025

2025年4月29日

/PRNewswire/ -- AlphaRose Therapeutics, an advanced preclinical-stage biotechnology company focused on developing and commercializing therapeutics for neurogenetic developmental diseases, today announces the acquisition of Alpha Anomeric SA, a French company with a novel proprietary oligonucleotide chemistry platform (abcDNA).

/PRNewswire/ -- AlphaRose Therapeutics，一家专注于开发和商业化用于神经遗传发育疾病的治疗方法的先进临床前阶段生物技术公司，今天宣布收购法国公司 Alpha Anomeric SA，该公司拥有一个新型专有的寡核苷酸化学平台（abcDNA）。

AlphaRose is currently advancing its lead antisense oligonucleotide product, Rosiphersen, through IND-enabling studies with a goal of initiating clinical studies in early 2026. AlphaRose is also developing a novel gene control technology platform and the Alpha Anomeric chemistry platform has the potential to become an integral part of the AlphaRose platform and development programs.

AlphaRose目前正在通过IND支持性研究推进其领先的反义寡核苷酸产品Rosiphersen，并计划在2026年初启动临床研究。AlphaRose还在开发一种新型基因控制技术平台，而Alpha Anomeric化学平台有潜力成为AlphaRose平台及其开发项目的重要组成部分。

Terms of the transaction were not disclosed..

交易条款未披露。

Alpha Anomeric is a French company founded to develop a novel oligonucleotide chemistry platform ('abcDNA') invented at the University of

Alpha Anomeric是一家法国公司，创立目的是开发一种新型寡核苷酸化学平台（“abcDNA”），该平台是在大学发明的。

Bern

伯尔尼

(CH) by Professor

（中国）教授

Christian Leumann

克里斯蒂安·勒曼

and Doctor

和医生

Damien Evoquez

达米安·埃沃凯兹

. Alpha Anomeric was founded by Doctor

阿尔法异常公司由博士创立

Wolfgang Renner

沃尔夫冈·伦纳

together with lead investor Advent Life Sciences and has validated the potential for the technology to be applied broadly in oligonucleotide therapeutic constructs. The novel chemistry platform is designed to enhance the safety, efficacy and applicability of oligonucleotide therapeutics in a variety of disease settings..

与主要投资者Advent Life Sciences共同参与，并已验证该技术在寡核苷酸治疗构建体中的广泛应用潜力。这一新型化学平台旨在增强寡核苷酸治疗药物在多种疾病环境中的安全性、有效性和适用性。

AlphaRose will maintain Alpha Anomeric as a subsidiary headquartered in

阿尔法玫瑰将保留阿尔法异构体作为其总部位于

Paris, France

法国巴黎

. In addition to the technology platform, the acquisition provides a European presence for AlphaRose and adds an important dimension to AlphaRose's plans to commercialize its products on a global basis, including throughout

除了技术平台之外，此次收购还为AlphaRose提供了欧洲市场的立足点，并为其计划在全球范围内（包括整个欧洲）将其产品商业化的计划增添了重要的维度。

Europe

欧洲

。

'We are thrilled to join with Alpha Anomeric and we look forward to exploring and building on the full potential of their technology,' stated AlphaRose Founder and CEO,

“我们非常高兴能与Alpha Anomeric合作，我们期待着探索并充分挖掘其技术的潜力，”AlphaRose创始人兼首席执行官表示。

Casey McPherson

凯西·麦克弗森

. He added, 'With our focus on oligonucleotide therapeutics for neurogenetic developmental disorders and more broadly in rare genetic disorders the abcDNA technology is well-positioned to establish and differentiate AlphaRose as a leader in the oligonucleotide therapeutic space.'

他补充道：“由于我们专注于神经遗传发育障碍以及更广泛的罕见遗传疾病的寡核苷酸疗法，abcDNA技术有望确立并使AlphaRose在寡核苷酸治疗领域中脱颖而出，成为领导者。”

'We are pleased that AlphaRose is acquiring Alpha Anomeric and recognizes the potential of the technology,' stated Dr.

“我们很高兴AlphaRose收购了Alpha Anomeric，并且认识到了该技术的潜力，”博士表示。

Wolfgang Renner

沃尔夫冈·伦纳

, Founder and former CEO of Alpha Anomeric. 'Our work has demonstrated the potential of the technology and we look forward to seeing it now be applied to therapeutic development at AlphaRose.'

阿尔法异构体公司的创始人兼前首席执行官表示：“我们的工作已经证明了这项技术的潜力，我们期待看到它现在在AlphaRose应用于治疗开发。”

'We are grateful to the team at Alpha Anomeric, Advent and University of

“我们感谢Alpha Anomeric、Advent和大学的团队，

Bern

伯尔尼

for the work they have done to develop the abcDNA technology and for their support of the acquisition by AlphaRose,' stated

为了他们开发abcDNA技术所做的工作以及他们对AlphaRose收购的支持，'

Alan Walts

艾伦·沃尔茨

, Executive Chairman of AlphaRose. 'We look forward to advancing the technology within AlphaRose and to positioning the technology for use by other companies working to develop next generation oligonucleotide therapies.'

阿尔法罗斯公司执行主席表示：“我们期待在阿尔法罗斯内部推进这项技术，并将该技术定位为其他致力于开发下一代寡核苷酸疗法的公司所用。”

About AlphaRose Therapeutics

关于AlphaRose治疗学

AlphaRose is a public benefit corporation focused on creating scalable precision medicine treatments for the 400 million patients worldwide with rare genetic diseases, beginning with children. These diseases often lack effective treatments and present significant challenges in the drug development process, particularly for children.

AlphaRose 是一家公共利益公司，专注于为全球 4 亿患有罕见遗传病的患者创造可扩展的精准医疗方案，首先从儿童开始。这些疾病通常缺乏有效的治疗方法，并且在药物开发过程中面临重大挑战，尤其是针对儿童的治疗。

AlphaRose aims to bridge this gap by developing targeted therapies for specific genetic mutations within these smaller patient populations. Rare genetic diseases collectively affect 1 in 10 people, approximately half of whom are children. While individually rare, collectively this is a larger population than cancer and AIDS combined.

阿尔法玫瑰公司旨在通过为这些较小患者群体中的特定基因突变开发靶向治疗来弥合这一差距。罕见遗传病总体影响十分之一的人，其中大约一半是儿童。尽管每种疾病单独来看很罕见，但综合起来，其影响的人口比癌症和艾滋病的总和还要多。

In the US alone, these diseases create an annual economic burden estimated to be nearly .

仅在美国，这些疾病每年造成的经济负担估计接近。

one trillion dollars

一万亿美元

. Despite the identification of 10,000 rare genetic diseases through genetic sequencing, 95% still lack treatments. Traditional drug development models often do not support developing therapies for these diseases due to the small patient populations involved and the high costs of typical drug development.

尽管通过基因测序已经鉴定出10,000种罕见遗传疾病，但其中95%仍然缺乏治疗手段。传统药物开发模式通常不支持为这些疾病开发疗法，因为涉及的患者群体较小，且典型的药物开发成本高昂。

AlphaRose reimagines a new model for drug development to address these underserved populations. By utilizing programmable genetic medicines, economies of scale, a systematic approach, and advanced technologies, the company aims to create a precision medicine model that can rapidly make and deploy to patients treatments for many genetic diseases. .

AlphaRose 重新构想了一种新的药物开发模式，以满足这些服务不足的群体。通过利用可编程基因药物、规模经济、系统化方法和先进技术，该公司旨在创建一种精准医学模式，能够快速为许多遗传病患者制造并部署治疗方案。

AlphaRose is based in

阿尔法玫瑰公司位于

Austin, TX

德克萨斯州奥斯汀市

and was founded in

成立于

October 2023

2023年10月

. The company has established a partnership with the To Cure a Rose Foundation (TCAR), and holds an exclusive worldwide license from TCAR for the intellectual property associated with AlphaRose's lead product, Rosiphersen. This license covers multiple compound designs and chemistries for antisense oligonucleotides that affect expression of the HNRNPH2 gene. .

公司已与“To Cure a Rose Foundation”（TCAR）建立了合作伙伴关系，并从TCAR获得了关于AlphaRose主要产品Rosiphersen相关知识产权的全球独家许可。该许可涵盖了影响HNRNPH2基因表达的反义寡核苷酸的多种化合物设计和化学技术。

AlphaRose is building a patient-centric model, focusing on precision and scalability to address neurogenetic diseases. The company is collaborating with researchers, clinicians, and families to ensure its therapies are both impactful and accessible. While initially focused on HNRNPH2 disorders, AlphaRose has identified over 300 other potential pediatric disease targets using its AI/ML algorithms and has begun development on some of these.

AlphaRose 正在构建一个以患者为中心的模型，专注于精准性和可扩展性，以应对神经遗传疾病。该公司正与研究人员、临床医生和家庭合作，确保其疗法既具影响力又易于获取。虽然最初关注 HNRNPH2 疾病，但 AlphaRose 已利用其人工智能/机器学习算法鉴定了 300 多种其他潜在的儿科疾病靶点，并已开始针对其中一些展开开发。

The company is actively seeking research grants and pursuing strategic partnerships to build a robust pipeline of genetic medicines..

公司正在积极寻求研究资助，并追求战略合作伙伴关系，以建立强大的基因药物管道。

About Alpha Anomeric

关于阿尔法异头物

Alpha Anomeric was founded in 2018 to develop a novel oligonucleotide chemistry invented at the University of

Alpha Anomeric 公司于 2018 年成立，旨在开发一种在大学发明的新型寡核苷酸化学技术。

Bern

伯尔尼

, referred to as abcDNA. We believe this is the first and only antisense chemistry to both eliminate sulphur and retain a charged backbone developed in the last 20 years. The key features of the technology are manifold:

，称为abcDNA。我们相信这是过去20年中开发的第一种也是唯一一种既能消除硫又能保持带电主链的反义化学技术。该技术的主要特点有很多：

abcDNA eliminates the dose-limiting toxicity of phosphorothioates improving therapeutic index and specificity of targeting

abcDNA消除了硫代磷酸酯的剂量限制性毒性，提高了治疗指数和靶向特异性

abcDNA oligonucleotides retain a charged phosphate backbone, maintaining strong and specific target RNA binding and efficacy

abcDNA寡核苷酸保持带电的磷酸骨架，保持与目标RNA的强特异结合和功效

abcDNA oligonucleotides are nuclease resistant and compatible with all current targeting approaches

abcDNA寡核苷酸具有核酸酶抗性，并且与所有当前的靶向方法兼容。

abcDNA oligonucleotides are active

abcDNA寡核苷酸是活跃的

in vivo

体内

in AON applications including exon skipping, exon inclusion and RNase H mediated RNA decay (gapmer technology)

在AON应用中，包括外显子跳跃、外显子包含和RNase H介导的RNA降解（gapmer技术）

Alpha Anomeric's abcDNA has broad IP coverage with issued patents covering abcDNA monomers & oligomers, and management believes that CMC provides scalability and low cost of goods.

Alpha Anomeric的abcDNA拥有广泛的知识产权覆盖，已获专利涵盖abcDNA单体和寡聚体，管理层相信CMC提供了可扩展性和低成本的商品生产。

For inquiries regarding the abcDNA technology and for partnering with AlphaRose:

有关abcDNA技术的咨询以及与AlphaRose合作事宜：

cmcpherson@alpharose.com

Contact:

联系人：

Sean Mahoney

肖恩·马洪

for AlphaRose Therapeutics

适用于AlphaRose Therapeutics

394095@email4pr.com

310-867-0670